Oluremi Oladipo Oladele
Research Subjects
Oluremi Oladipo Oladele has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Victor Olufolahan Lasebikan
Department of Psychiatry, College of Medicine, University of Ibadan, Ibadan, Nigeria
3 shared publications - Morufat Abosede Alabi2 shared publications
- Oyeyemi Afolabi2 shared publications
- Tiwatayo Olufolahan Lasebikan2 shared publications
- Victor Makanjuola
Department of Psychiatry, University of Ibadan, Ibadan, Nigeria
2 shared publications - Abdulrahamon Sikirullah1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by Ternopil State Medical University in International Journal of Medicine and Medical Research
- Vol. 12 (1) , 6-13
Plasma levels of quinolinic acid and kynurenic acid in patients with major mental illnesses
Clarifying antipsychotic effects on kynurenine-pathway metabolites may improve understanding of their role in major mental illnesses. Therefore, this study aimed to assess plasma quinolinic and kynurenic acid levels in patients with major mental illnesses. 85 adults comprising 55 treatment-experienced patients with major mental illnesses; schizophrenia, bipolar and depression, and 30 controls were enrolled into this study. The plasma levels of quinolinic acid and kynurenic acid were determined using Enzyme Linked Immunosorbent Assay. Plasma quinolinic acid level was significantly lower in patients with major mental illnesses (14.52 (7.16-48.24) mg/mL) compared with the controls (157.79 (68.64-464.05) mg/mL). In contrast, plasma kynurenic acid level was higher in patients with major mental illnesses (243.96 (210.65-283.05) μmol/L) compared with the controls (215.36 (185.67-243.65) μmol/L). After stratification into groups, patients with schizophrenia (22.86 (7.62-53.14) mg/mL), bipolar (15.34 (8.37-48.21) mg/mL) and depression (6.18 (2.66-43.05) mg/mL) had significantly lower quinolinic acid levels compared with the controls (157.79 (68.64-464.05) mg/mL). However, kynurenic acid levels were only significantly elevated in patients with schizophrenia (247.0 (208.34-290.22 μmol/L) and bipolar (243.20 (212.85-291.12) μmol/L) compared with the controls (215.36 (185.67-243.65) μmol/L). The plasma levels of quinolinic acid and kynurenic acid did not differ significantly among patients with schizophrenia, bipolar disorder, and depression. Treated patients with major mental illnesses exhibited a kynurenine metabolite profile indicative of reduced neurotoxicity and enhanced neuroprotection. These metabolites may serve as potential biomarkers for monitoring treatment effects Received: 27.12.2025 | Revised: 16.04.2026 | Accepted: 26.05.2026
- 29 May 2026
- Published by Ternopil State Medical University in International Journal of Medicine and Medical Research
- Vol. 12 (1) , 6-13
Open AccessPlasma levels of quinolinic acid and kynurenic acid in patients with major mental illnesses
Clarifying antipsychotic effects on kynurenine-pathway metabolites may improve understanding of their role in major mental illnesses. Therefore, this study aimed to assess plasma quinolinic and kynurenic acid levels in patients with major mental illnesses. 85 adults comprising 55 treatment-experienced patients with major mental illnesses; schizophrenia, bipolar and depression, and 30 controls were enrolled into this study. The plasma levels of quinolinic acid and kynurenic acid were determined using Enzyme Linked Immunosorbent Assay. Plasma quinolinic acid level was significantly lower in patients with major mental illnesses (14.52 (7.16-48.24) mg/mL) compared with the controls (157.79 (68.64-464.05) mg/mL). In contrast, plasma kynurenic acid level was higher in patients with major mental illnesses (243.96 (210.65-283.05) μmol/L) compared with the controls (215.36 (185.67-243.65) μmol/L). After stratification into groups, patients with schizophrenia (22.86 (7.62-53.14) mg/mL), bipolar (15.34 (8.37-48.21) mg/mL) and depression (6.18 (2.66-43.05) mg/mL) had significantly lower quinolinic acid levels compared with the controls (157.79 (68.64-464.05) mg/mL). However, kynurenic acid levels were only significantly elevated in patients with schizophrenia (247.0 (208.34-290.22 μmol/L) and bipolar (243.20 (212.85-291.12) μmol/L) compared with the controls (215.36 (185.67-243.65) μmol/L). The plasma levels of quinolinic acid and kynurenic acid did not differ significantly among patients with schizophrenia, bipolar disorder, and depression. Treated patients with major mental illnesses exhibited a kynurenine metabolite profile indicative of reduced neurotoxicity and enhanced neuroprotection. These metabolites may serve as potential biomarkers for monitoring treatment effects Received: 27.12.2025 | Revised: 16.04.2026 | Accepted: 26.05.2026
- 20 June 2025
- Published by Taylor & Francis
- p. 30-42
Frontotemporal Dementia and Drug Addiction
- 20 June 2025
- Published by Taylor & Francis
- p. 68-79
Alcohol and Neurogenerative Disorders